# Shanghai Zhihuilin Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-zhihuilin-medical-technology-co

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.gwell.tech
- Total disclosed funding: $19M
- Latest round: Series B (Jan 27, 2021)
- Investors on record: 3

## About

Established in 2014 and based in Shanghai, China, Shanghai Zhihuilin Medical Technology Co., Ltd. is a medical company that provides nursing large screens, logistics robots, life-things systems products. The company also established a factory in Jiangsu. In September 2017, company's Noah® 2 series hospital logistics robot obtained China Robot Certification (CR) certificate. In January 2018, the company was awarded as a member of the National Artificial Intelligence Standardization Group and a member of the National Artificial Intelligence Standard Drafting Group. The company has possessed more than 200 patents.

The company provides logistics solutions for hospitals through a hospital-wide intelligent real-time dispatch system, coupled with safe and efficient driverless technology based on 5G technology. The company has launched 23 models, which can cover 21 application scenarios and can meet 95% of the material transportation needs of the hospital. The company has cooperated with Tongji Hospital, The First Hospital of China Medical University, Zhujiang Hospital of South Medical University and other hospitals.

The company will focuses on product development and marketing.

## Funding rounds

- Series B, Jan 27, 2021, $19M — Wuxi Guolian Development (Group), Shenzhen Zhongke Incubation Equity Investment Fund Management
- Series A, Sep 2, 2019 — Shanshan Venture Capital

## Investors

- Shanshan Venture Capital (https://capitalatlas.ai/funds/shanshan-venture-capital) — Series A
- Wuxi Guolian Development (Group) — Series B
- Shenzhen Zhongke Incubation Equity Investment Fund Management (https://capitalatlas.ai/funds/shenzhen-zhongke-incubation-equity-investment-fund-managemen) — Series B